Press Releases

PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren...

PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase 2 clinical...

Celator Pharmaceuticals completes enrollment in a second phase 2...

Celator Pharmaceuticals announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage...

Eurand Presents Data on ZENPEP(R) Without Proton Pump Inhibitors...

Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. announced additional data from a post-hoc analysis of a Phase III clinical trial...

Cephalon Announces FDA Approval of Risk Evaluation and Mitigation...

Cephalon, Inc. (Nasdaq: CEPH) today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGIL(R) (armodafinil) Tablets and PROVIGIL(R) (modafinil) Tablets ...

FDA approves Herceptin for HER2-positive metastatic stomach cancer

Roche announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil ) for...

Amylin, Lilly and Alkermes Announce Receipt of Complete Response...

Amylin Pharmaceuticals, Inc. Eli Lilly and Company and Alkermes, Inc.announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding...

AVEVA to Exhibit at Drug Delivery Partnerships 2011

Aveva Drug Delivery Systems is pleased to announce that it will exhibit at Drug Delivery Partnerships on 26-28 January 2011 in Miami, Florida,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read